Insulet Corporation
Insulet Corporation Announces Issuance of Senior Notes and Amendment to Credit Agreement
Summary
Insulet Corporation announced on March 20, 2025, the issuance and sale of $450 million aggregate principal amount of 6.50% Senior Notes due 2033. Simultaneously, the company amended its Credit Agreement to extend the maturity and increase the revolving credit commitments to $500 million. The net proceeds from the notes offering are expected to be approximately $444 million, after deducting initial purchasers' discounts and commissions. In addition, the company entered into agreements to repurchase $419 million aggregate principal amount of its outstanding 0.375% Convertible Senior Notes due 2026.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement